Role of TNF-α in the mechanisms responsible for preterm delivery induced by Stx2 in rats

Br J Pharmacol. 2013 Feb;168(4):946-53. doi: 10.1111/j.1476-5381.2012.02239.x.

Abstract

Background and purpose: Infections with a strain of Escherichia coli producing Shiga toxins could be one of the causes of fetal morbidity and mortality in pregnant women. We have previously reported that Shiga toxin type 2 (Stx2) induces preterm delivery in pregnant rats. In this study, we evaluate the role of TNF-α, PGs and NO in the Stx2-induced preterm delivery.

Experimental approach: Pregnant rats were treated with Stx2 (0.7 ng g(-1)) and killed at different times after treatment. Placenta and decidua were used to analyse NOS activity by the conversion of L-[(14)C]arginine into L-[(14)C]citrulline, levels of PGE(2) and PGF(2α) assessed by radioimmunoassay, and cyclooxygenase (COX) proteins by Western blot. TNF-α level was analysed in serum by ELISA and by cytotoxicity in L929 cells. The inhibitor of inducible NOS, aminoguanidine, the COX-2 inhibitor, meloxicam, and the competitive inhibitor of TNF-α, etanercept, were used alone or combined to inhibit NO, PGs and TNF-α production respectively, to prevent Stx2-induced preterm delivery.

Key results: Stx2 increased placental PGE(2) and decidual PGF(2α) levels as well as COX-2 expression in both tissues. Aminoguanidine and meloxicam delayed the preterm delivery time but did not prevent it. Etanercept blocked the TNF-α increase after Stx2 treatment and reduced the preterm delivery by approximately 30%. The combined action of aminoguanidine and etanercept prevented Stx2-induced preterm delivery by roughly 70%.

Conclusion and implications: Our results demonstrate that the increased TNF-α and NO induced by Stx2 were the predominant factors responsible for preterm delivery in rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cyclooxygenase 2 / biosynthesis
  • Decidua / drug effects
  • Decidua / enzymology
  • Decidua / metabolism
  • Dinoprost / biosynthesis*
  • Dinoprostone / biosynthesis*
  • Drug Therapy, Combination
  • Etanercept
  • Female
  • Guanidines / administration & dosage
  • Guanidines / therapeutic use
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / therapeutic use
  • Nitric Oxide / biosynthesis
  • Placenta / drug effects
  • Placenta / enzymology
  • Placenta / metabolism
  • Pregnancy
  • Premature Birth / blood
  • Premature Birth / chemically induced*
  • Premature Birth / metabolism
  • Premature Birth / prevention & control
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Shiga Toxin 2 / toxicity*
  • Tumor Necrosis Factor-alpha / blood*

Substances

  • Guanidines
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Shiga Toxin 2
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • Dinoprost
  • Cyclooxygenase 2
  • Ptgs2 protein, rat
  • Dinoprostone
  • Etanercept
  • pimagedine